REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
12 hedge funds and large institutions have $10.5M invested in REVIVA PHARMA HLDGS INC in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
9.3% less ownership
Funds ownership: 28.74% → 19.44% (-9.3%)
17% less capital invested
Capital invested by funds: $12.8M → $10.5M (-$2.23M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$105K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$97.9K |
| 3 |
BlackRock
New York
|
+$59.8K |
| 4 |
HF
HRT Financial
New York
|
+$53.1K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$331K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$80.5K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$61K |
| 4 |
Renaissance Technologies
New York
|
-$55K |
| 5 |
DC
Davenport & Co
Richmond,
Virginia
|
-$49K |
RVPH Hedge Fund Activity: Q3 2021 in Review
12 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q3 2021, worth a combined $10.5M — down 17% from $12.8M a quarter earlier.
Fund positioning in RVPH was balanced in Q3 2021: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $105K. The largest seller was Armistice Capital, cutting an estimated $331K.
- 12 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $10.5M of REVIVA PHARMA HLDGS INC stock for Q3 2021, down 17% quarter-over-quarter.
- 3 funds opened new REVIVA PHARMA HLDGS INC positions in Q3 2021 and 3 closed out, a net change of 0 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q3 2021 was Susquehanna International Group, an estimated $105K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q3 2021 was Armistice Capital, an estimated $331K sold.
Based on aggregated 13F filings for Q3 2021.